Skip to main content
OpenTrials

Clinical trial condition

Multiple Myeloma

Explore clinical trials studying Multiple Myeloma. Study availability and eligibility vary by location and protocol.

1,661 public trials 325 recruiting studies
Refine in advanced search Browse all conditions

Multiple Myeloma trial results

Recruiting

A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

NCT06980480

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
Locations
  • Infirmary Health - Diagnostic & Medical Clinic (DMC) Mobile, Alabama, United States
  • Chao Family Comprehensive Cancer Center UCI Orange, California, United States
  • University of Kansas Westwood, Kansas, United States
  • University of Maryland | Greenebaum Cancer Center Baltimore, Maryland, United States
View all 42 locations
View Trial Details
Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

NCT05469893

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +16 more
Locations
  • Colorado Blood Cancer Institute Denver, Colorado, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
  • Oregon Health & Science University Portland, Oregon, United States
View Trial Details
Recruiting

A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma

NCT07258511

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • UAMS Little Rock, Arkansas, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • University of California San Francisco San Francisco, California, United States
  • Colorado Blood Cancer Institute Denver, Colorado, United States
View all 109 locations
View Trial Details
Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

NCT06121843

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Mayo Clinic in Arizona - Phoenix Phoenix, Arizona, United States
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View all 19 locations
View Trial Details
Recruiting

Selinexor and Backbone Treatments of Multiple Myeloma Patients

NCT02343042

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Disease Attributes, +16 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Jonnsson Comprehensive Cancer Center / University of Los Angeles Los Angeles, California, United States
  • Sarah Cannon-Colorado Blood Cancer Institute Denver, Colorado, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
View all 25 locations
View Trial Details
Recruiting

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

NCT06182774

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Cross Cancer Institute Edmonton, Alberta, Canada
  • BCCA - Kelowna Kelowna, British Columbia, Canada
  • BCCA - Vancouver Vancouver, British Columbia, Canada
  • CancerCare Manitoba Winnipeg, Manitoba, Canada
View all 28 locations
View Trial Details
Recruiting

AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma

NCT06106945

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Research Site Duarte, California, United States
  • Research Site Irvine, California, United States
  • Research Site Atlanta, Georgia, United States
  • Research Site Boston, Massachusetts, United States
View all 43 locations
View Trial Details
Recruiting

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT05650632

Conditions
Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +12 more
Locations
  • Mayo Clinic Arizona /ID# 251405 Phoenix, Arizona, United States
  • Highlands Oncology Group - Springdale /ID# 267742 Springdale, Arkansas, United States
  • Rocky Mountain Cancer Centers - Aurora /ID# 268574 Aurora, Colorado, United States
  • Medical Oncology Hematology Consultants /ID# 268560 Newark, Delaware, United States
View all 46 locations
View Trial Details

Related conditions